For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Jump To
Testing Portfolio
What is Genomic Testing?
Genomic testing is a process by which clinicians study the activity and interaction of genes within the human body. The Weill Cornell Medicine Clinical Genomics Laboratory facilitates genomic testing assessments of mutations in roughly 22,000 different human genes. These assessments provide clinically actionable diagnoses for personalized patient care. Our highly trained professional staff members use genomic tests to identify alterations in genes that cause cancer to grow and spread within the body, determine the genetic drivers of these mutations and provide insights for disease treatment.
How Genomic Tests Work
The genomic testing process is designed to provide high-quality information for patients as quickly and accurately as possible. We integrate the latest sequencing technology with the insights of a highly professional and skilled team of pathologists, computational biologists and scientists to help clinicians and translational researchers identify the best possible treatment decisions for their patients. Our EXaCT-1 clinical genomic test, the first whole-exome sequencing, clinical cancer test approved by the state of New York, allows for examination of the genomic mutations of all genes in each patient’s cancer cells and generally requires only three-four weeks to deliver results after samples arrive in our laboratory.
Available Tests
| Test Name | Indication | Type | # of Genes | Turnaround Time | Ordering Instructions |
|---|---|---|---|---|---|
| EXaCT-1 (Whole-Exome Sequencing) | Comprehensive profile of all genes within cancer cells – EXaCT-1 facilitates a more complete understanding of a patient’s cancer through evaluation of an entire tumor exome. | Solid tumor and hematologic malignancies | ~22,000 | 3-4 weeks | |
| 50-Gene | Mutations in lung, colon, rectum, thyroid, brain and skin cancer | Solid tumors | 50 | 7-14 days | |
| My Heme Panel | Mutation status of recurrently mutated genes in patients with myeloid neoplasms | Hematopoietic myeloid neoplasms | 45 | 5-10 days | |
| Oncomine | Clinically significant somatic mutations | Solid neoplasms | 143, including RNA fusions | 10-14 days |
There are currently no Genomic Tests in that category.
